Sarcoidosis and COVID-19 Impact Survey
The survey aims to answer questions including:
- Is a sarcoidosis patient more likely to get COVID-19 infection?
- If a sarcoidosis patient becomes infected, does he or she have a worse outcome?
- Is there increased risk if a patient is taking prednisone or other immunosuppressive drugs?
- Does taking hydroxychloroquine protect a sarcoid patient from COVID-19?
- Does race affect the risk or the outcome for COVID-19?
To date, over 1600 sarcoidosis patients have responded to the survey. Of these, only 31 patients – less than 2%– reported having COVID-19. Most were able to be treated at home and none required mechanical ventilation. Researchers were unable to identify an increased risk associated with race, use of prednisone, or treatment with infliximab (Remicade). Also, the use of hydroxychloroquine (plaquenil) was neither protective nor a risk factor for infection. The study is ongoing and will include a follow up questionnaire in July.